Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes, Insights From the PEGASUS TIMI 54 Trial



Ticagrelor is a potent reversible P2Y12 inhibitor that reduces ischemic risk in patients with acute coronary syndromes and in those who need long‐term secondary prevention after myocardial infarction (MI).

Copyright © 2020 Terumo India Private limited

X
Important information regarding

By using this website, you consent to the use of cookies in accordance with our